Overview

This trial is active, not recruiting.

Condition open angle glaucoma
Treatment two trabecular micro-bypass stents (istent inject)
Phase phase 4
Sponsor Glaukos Corporation
Start date March 2013
End date March 2015
Trial size 57 participants
Trial identifier NCT02868190, GCF-038

Summary

This study objective is to evaluate the intraocular pressure (IOP) lowering effect of two trabecular micro-bypass stents (iStent inject) in eyes of subjects with primary open-angle glaucoma on one topical hypotensive medication

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Other)
Standalone implantation of two trabecular micro-bypass stents (iStent inject)
two trabecular micro-bypass stents (istent inject)
Standalone implantation of two trabecular micro-bypass stents (iStent inject)

Primary Outcomes

Measure
Mean intraocular pressure reduction of 20% or more vs baseline
time frame: 12 months post-op

Secondary Outcomes

Measure
Proportion of subjects with intraocular pressure less than or equal to 18 mm Hg
time frame: 12 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Phakic patients or pseudophakic patients with posterior chamber intraocular lenses (PC-IOLs) Primary open-angle glaucoma (including pigmentary or pseudoexfoliative) C/D ratio ≤ 0.9 Visual field defects, or nerve abnormality characteristic of glaucoma One topical hypotensive medication at time of screening exam Intraocular pressure (IOP) > 18 mmHg and ≤ 30 mmHg (medicated) at screening exam Study eye BCVA 20/100 or better Normal angle anatomy as determined by gonioscopy Absence of peripheral anterior synechia (PAS), rubeosis or other angle abnormalities that could impair proper placement of stent Able and willing to attend scheduled follow-up exams Able and willing to provide written informed consent on the approved Informed Consent Form Baseline Exam Inclusion Criteria: Subject has completed appropriate medication washout Mean IOP > 22 mmHg and ≤ 38 mmHg after anti-glaucoma medication washout period Exclusion Criteria: Screening Exam Exclusion Criteria: Aphakic patients or pseudophakic patients with anterior chamber IOLs (AC-IOLs) Prior stent implantations (study eye) Traumatic, uveitic, neovascular, or angle-closure glaucoma; or glaucoma associated with vascular disorders Functionally significant visual field loss, including severe nerve fiber bundle defects such as Bjerrum scotoma Prior incisional glaucoma surgery Prior SLT within 90 days prior to screening Prior ALT Iridectomy or laser iridotomy Ineligibility for ocular hypotensive medication washout period as determined by the investigator such as: visual field status would be placed at risk by washout period unmedicated IOP after washout period would be expected to exceed upper limit of ≥ 38 mmHg Any active corneal inflammation or edema (e.g., keratitis, keratoconjunctivitis, keratouveitis) Clinically significant corneal dystrophy (e.g., bullous keratopathy, Fuch's dystrophy); any guttata Corneal surgery (prior or anticipated) of any type (including LASIK, LASEK, PRK, etc.) that may interfere with IOP measurement reliability Corneal opacities or disorders that would inhibit visualization of the nasal angle Congenital or traumatic cataract Retinal or optic nerve disorders, either degenerative or evolutive, that are not associated with the existing glaucoma condition Elevated episcleral venous pressure such as associated with: active thyroid orbitopathy cavernous sinus fistula Sturge-Weber syndrome orbital tumors orbital congestive disease Clinically significant sequelae from trauma (e.g., chemical burns, blunt trauma, etc.) Chronic ocular inflammatory disease or presence of active ocular inflammation (e.g., uveitis, iritis, iridocyclitis, retinitis) Pregnant or nursing women Baseline Exam Exclusion Criteria: Subject did not complete medication washout Mean IOP < 22 mmHg or > 38 mmHg after anti-glaucoma medication washout Subject did not have a 3mmHg IOP increase over screening mean diurnal Prohibited Concomitant Medications None

Additional Information

Official title A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication (Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject)
Principal investigator Lilit Voskanyan, MD, PhD
Description The study design is as follows: Prospective Subjects with medicated IOP > 18 mmHg and ≤ 30 mmHg Subjects on one topical ocular hypotensive medication prior to stent implantation Implantation of two iStent devices (if IOP is < 6 mmHg, at any point during the postoperative follow-up, medication will not be prescribed or will be discontinued) IOP will be measured by two (2) observers to minimize bias; observer 1 will look through the slit lamp and turn the dial with readings being masked, and observer 2 will document the IOP Diurnal IOP measurements Follow-up through 60 months postoperative (but could be up to 61 months if subject needs to undergo terminal washout) Descriptive statistics will be tabulated Medical therapy considered necessary for the subject's welfare can be implemented at any time during the study at the investigator's discretion
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Glaukos Corporation.